propagermanium (Ge 132)

inhibits the calcium inward currents & the potassium outward currents

Also Known As:

Ge 132; SK 818; 3,3'-(1,3-dioxo-1,3-digermoxanediyl)dipropionic acid; 3-oxygermylpropionic acid polymer; Arlamol Gel; DCEFSQD; Ge-132; Germanium-132; SK-818; beta carboxyethylgermanium sesquioxide; bis(2-carboxyethyl)germanium sesquioxide; bis(carboxyethyl)germanium sesquioxide; carboxyethylgermanium sesquioxide; dicarboxyethenylgermanium sesquioxide; dihydrogen bis(2-carboxylatoethyl)trioxodigermanate(2-); poly-trans-((2-carboxyethyl)germasesquioxane); proxigermanium; repagermanium

Networked: 55 relevant articles (7 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Matsushima, Kouji: 4 articles (07/2004 - 02/2003)
2.	Nakamura, Takashi: 3 articles (01/2021 - 02/2011)
3.	Kitagawa, Kiyoki: 3 articles (07/2020 - 10/2003)
4.	Wada, Takashi: 3 articles (07/2020 - 10/2003)
5.	Arai, Hidenori: 3 articles (03/2010 - 09/2007)
6.	Kita, Toru: 3 articles (03/2010 - 09/2007)
7.	Ishiwata, Yoshiro: 3 articles (07/2004 - 02/2003)
8.	Shimada, Yasuhiro: 2 articles (01/2021 - 02/2011)
9.	Iwata, Yasunori: 2 articles (07/2020 - 10/2003)
10.	Jomori, Takahito: 2 articles (03/2020 - 09/2019)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2019 - "Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium." 09/01/2019 - "Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer." 09/01/1993 - "Researches explained that the effect of cancer prevention of CMS was better than that of Ge-132." 09/01/1993 - "In Ge-132 only the mean cancer foci and the mean cancer volumes/rat were found significantly less than controls (P < 0.01). " 07/01/1987 - "Also, tumor-bearing mice treated exogenously with this antiserum did not differ significantly in survival as compared to controls, despite the administration of Ge-132. "
2.	Ascites 11/01/1985 - "Sera from C57Bl/6 mice treated orally with Ge-132 exhibited antitumour activity against Ehrlich (allogeneic) and RL male 1 (syngeneic) ascites tumours in BALB/c mice. " 09/01/1985 - "This suggests that Ge-132 was effective against certain ascites tumors regardless of whether the tumor was syngeneic or allogeneic. " 07/01/1985 - "These results suggest that Ge-132 is effective against certain ascites tumors regardless of whether the tumor is syngeneic or allogeneic. " 09/01/1985 - "The purpose of this study was to investigate the effective mechanisms of Ge-132, an organogermanium compound with immunomodulatory activity, on experimental murine ascites tumors. " 07/01/1987 - "Therefore, the antitumor mechanism of Ge-132 in the murine ascites tumor system may be expressed as follows: (a) Ge-132 stimulates T-cells to induce IFN gamma when mice are treated orally with the compound, (b) IFN gamma activates macrophages to become cytotoxic, and (c) the cytotoxic macrophages eliminate tumor cells."
3.	Inflammation (Inflammations) 01/01/2017 - "Histopathological analysis of liver demonstrated that propagermanium treatment decreased macrovesicular steatosis and tended to reduce lobular inflammation, with more pronounced effects in the early intervention group. " 01/01/2017 - "Herein, we examined whether intervention with propagermanium, an inhibitor of CCR2, would attenuate tissue inflammation and NASH development. " 12/01/2008 - "Further, propagermanium suppressed macrophage accumulation and inflammation in adipose tissue. " 01/01/2017 - "Overall, early propagermanium administration was more effective to improve insulin resistance, WAT inflammation and NASH compared to late intervention. " 03/31/2010 - "Thus, propagermanium improved diet-induced obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. "
4.	Insulin Resistance 01/01/2017 - "The subsequent CCR2 intervention experiment showed that early, but not late, propagermanium treatment attenuated insulin resistance. " 01/01/2017 - "Overall, early propagermanium administration was more effective to improve insulin resistance, WAT inflammation and NASH compared to late intervention. " 03/31/2010 - "Thus, propagermanium improved diet-induced obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. " 12/01/2008 - "Propagermanium improved obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. " 01/01/2017 - "The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis."
5.	Obesity 03/31/2010 - "Thus, propagermanium improved diet-induced obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. " 12/01/2008 - "Propagermanium improved obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. " 12/01/2008 - "Our data indicate that inhibition of CCR2 could improve obesity and type 2 diabetes by interfering adipose tissue inflammation, and that propagermanium may be a beneficial drug for the treatment of the metabolic syndrome."

Related Drugs and Biologics

1.	anti-Thy antibody
2.	Trypan Blue
3.	Interferons
4.	Carrageenan
5.	Antigens
6.	Germanium
7.	CC Chemokines
8.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
9.	Triglycerides (Triacylglycerol)
10.	Polymers

Related Therapies and Procedures

1.	Therapeutics
2.	Lenses
3.	Vagotomy
4.	Injections
5.	Aftercare (After-Treatment)